Therapeutic efficacy of the ultimate formulation of Cupido nanoparticles

Home / eventi / Therapeutic efficacy of the ultimate formulation of Cupido nanoparticles

Cupido’s partner CNR, Finceramica and Plumestars have closely collaborated during this period to establish the first proof of concept of the therapeutic efficacy of the ultimate formulation of Cupido nanoparticles: a dry powder of Calcium-Phosphate nanoparticle (dpCaPs) loaded with a known therapeutic molecule. The tests have been performed on mice with a specific cardiac disease and their heart activity has been monitored by a non-invasive technique: echocardiography, which uses sound waves to produce live images of the heart and its valves.

Furthermore, the ultimate dpCaP formulation was administered via inhalation by a custom-made inhaler for small animals, which was generated and developed exclusively for CUPIDO. The first prototype of such a dry powder inhaler was improved based on the feedback collected in the first test campaign. The updated inhaler is now suitable for the first inhalation trials.

LinkedIn
Share